BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/22/2025 10:07:00 AM | Browse: 64 | Download: 82
 |
Received |
|
2024-08-11 13:30 |
 |
Peer-Review Started |
|
2024-08-11 13:30 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-12-17 09:57 |
 |
Revised |
|
2024-12-18 13:46 |
 |
Second Decision |
|
2024-12-25 02:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-12-25 07:37 |
 |
Articles in Press |
|
2024-12-25 07:37 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-01-06 03:14 |
 |
Publish the Manuscript Online |
|
2025-01-22 09:26 |
ISSN |
1948-9366 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Editorial |
Article Title |
Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Xue-Mei Yi, Hong-Qiao Cai and Yan Jiao |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Jilin Provincial Natural Science Foundation |
No. YDZJ202401650ZYTS |
|
Corresponding Author |
Yan Jiao, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com |
Key Words |
Programmed cell death receptor 1 inhibitor; Pembrolizumab; Advanced gastric cancer; Chemotherapy; Trastuzumab |
Core Tip |
In the past decade, programmed cell death receptor 1 (PD-1) inhibitors have shown significant anti-tumor effects and good safety in the treatment of various malignant tumors such as melanoma and non-small cell lung cancer. Multiple studies on advanced gastric cancer have shown that the combination therapy of PD-1 inhibitors can improve the efficacy. Pembrolizumab combined with chemotherapy or human epidermal growth factor receptor 2 targeting therapy have showed improved prognosis. In the future, it is important to explore the reasonable treatment sequence and dosage, to maximize the efficacy of combination therapy. |
Publish Date |
2025-01-22 09:26 |
Citation |
<p>Yi XM, Cai HQ, Jiao Y. Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer. <i>World J Gastrointest Surg</i> 2025; 17(2): 100257</p> |
URL |
https://www.wjgnet.com/1948-9366/full/v17/i2/100257.htm |
DOI |
https://dx.doi.org/10.4240/wjgs.v17.i2.100257 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345